Search Results for: Majority of Oncology Clinical Trials
Articles
Geron Announces Initiation of Janssen Phase II/III Clinical Trial January 18, 2016
Geron Corporation recently announced the dosing of the first patient in a Phase II/III clinical trial to evaluate imetelstat in...Oncology Leads Development in Promising Gene Therapy Pipeline September 24, 2015
Despite few products having so far reached the market and captured strong revenues, the gene therapy pipeline remains large, with...CLINICAL TRIALS - Outsourcing Early-Stage Clinical Trials: How to Mitigate Costs & Risk June 3, 2014
Roundtable Discussion: Contributor Cindy H. Dubin gathered leading CROs together to discuss the benefits of outsourcing early-stage clinical trials, how to mitigate the risks, and lower costs in the process.
Oligonucleotides & mRNA Vaccines Dominate in Strategic Alliances for RNA Therapies in Major APAC Countries April 26, 2024
RNA-based therapies have already proven and will continue to play an integral role in the development of novel therapeutic agents...Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program January 3, 2024
Intensity Therapeutics, Inc. recently announced a business update reflecting progress in its Phase 3 sarcoma clinical program. In the fourth...EXCIPIENT TECHNOLOGY - A Juggling Act: Factors at Play in Your Choice of Solubilizing Parenteral Excipients June 5, 2023
Joey Glassco, MBA, says the power of novel excipients such as Apisolex polymer could revolutionize the parenteral drug development landscape, effectively solubilizing a wide range of APIs without compromising on safety or stability.
Portage Biotech Reports Updated Interim Data for Lead iNKT Engager in Phase 1/2 Trial for the Treatment of Advanced Melanoma & Metastatic Non-Small Cell Lung Cancer June 5, 2023
Portage Biotech Inc. recently announced updated interim data from the Phase 1 portion of the trial evaluating its lead invariant...Elevar Therapeutics Submits NDA to FDA for Combination of Rivoceranib & Camrelizumab as First-Line Treatment Option for Unresectable Hepatocellular Carcinoma May 17, 2023
Elevar Therapeutics, Inc. recently announced it submitted an NDA to the US FDA for its investigational drug rivoceranib, an oral...DRUG-ELUTING IMPLANTS - Delivery of RNAi Therapeutics Through Drug-Eluting Implants April 3, 2023
Cyonna Holmes, PhD, Karen Chen, MS, and Brian Wilson, PhD, review how localized therapeutic delivery of these therapies through an implant provides an innovative route of administration for chronic conditions that are difficult to dose adequately.
Redx & Jounce Announce Recommended Business Combination February 23, 2023
Redx Pharma and Jounce Therapeutics, Inc. recently announce an unanimously recommended Business Combination of the two companies via a proposed...Stemline Therapeutics Receives Approval for First & Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer January 30, 2023
The Menarini Group recently announced the US FDA has approved ORSERDU for the treatment of postmenopausal women or adult men,...Urica Therapeutics Expands Exclusive License Agreement With Fuji Yakuhin Co. Ltd. December 14, 2022
Urica Therapeutics, Inc. recently announced it has expanded its exclusive license agreement with Fuji Yakuhin Co. Ltd. for the development...Genelux Corporation Initiates Pivotal Phase 3 Trial Evaluating Olvi-Vec for the Treatment of Platinum-Resistant/Refractory Ovarian Cancer September 21, 2022
Genelux Corporation recently announced it has initiated OnPrime, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and...Compass Therapeutics Reports Positive Interim Phase 2 Data May 4, 2022
Compass Therapeutics, Inc. recently reported additional interim results from a Phase 2 study of CTX-009 in combination with paclitaxel in...SPECIAL FEATURE - Solubility & Bioavailability: Utilizing Enabling Technologies March 1, 2022
Contributor Cindy H. Dubin interviews several leading companies on how they are using innovative technologies, such as lipid nanoparticles to achieve a high drug loading, combining anti-solvent continuous crystallization with micro-mixing technology to control crystallization and reduce crystal size, and how a robotic capsule can improve bioavailability in the range of 47% to 78%.
CordenPharma Collaborates With PeptiSystems on Continuous Peptide Manufacturing & Green Chemistry January 18, 2022
Due to the promising, yet underutilized potential of Green Chemistry and continuous manufacturing synthesis approaches gaining traction in the wider pharmaceutical community, CordenPharma recently announced a collaboration with PeptiSystems, a Swedish-based developer of….
Zai Lab Announces First Patient Treated in PANOVA-3 Phase 3 Pivotal Trial of Tumor Treating Fields in Pancreatic Cancer January 12, 2022
Zai Lab Limited recently announced treatment of the first patient in Greater China in the PANOVA-3 trial, a Phase 3...Checkpoint Therapeutics Announces Initiation of CONTERNO Phase 3 Trial of Cosibelimab Combined With Chemotherapy in Patients With First-Line Non-Squamous Non-Small Cell Lung Cancer December 8, 2021
Checkpoint Therapeutics, Inc. recently announced the initiation of the CONTERNO study, a global, randomized Phase 3 trial of cosibelimab in...Fortress Biotech, Cyprium Therapeutics & Sentynl Therapeutics Announce the Initiation of Rolling Submission of an NDA for Treatment of Menkes Disease December 7, 2021
Cyprium Therapeutics, Inc., a Fortress Biotech, Inc. partner company, with support from its licensing partner Sentynl Therapeutics, Inc., a wholly owned subsidiary of Cadila Healthcare Limited, recently announced the initiation of a rolling submission of a New Drug Application….